1. Home
  2. DTSS vs BIAF Comparison

DTSS vs BIAF Comparison

Compare DTSS & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Datasea Inc.

DTSS

Datasea Inc.

HOLD

Current Price

$1.30

Market Cap

10.9M

Sector

Technology

ML Signal

HOLD

Logo bioAffinity Technologies Inc.

BIAF

bioAffinity Technologies Inc.

HOLD

Current Price

$1.48

Market Cap

6.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DTSS
BIAF
Founded
2014
2014
Country
China
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.9M
6.6M
IPO Year
N/A
2022

Fundamental Metrics

Financial Performance
Metric
DTSS
BIAF
Price
$1.30
$1.48
Analyst Decision
Hold
Analyst Count
0
1
Target Price
N/A
N/A
AVG Volume (30 Days)
75.3K
86.9K
Earning Date
11-13-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$64,349,277.00
$6,776,739.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$20.04
P/E Ratio
N/A
N/A
Revenue Growth
68.56
N/A
52 Week Low
$1.03
$1.25
52 Week High
$3.10
$46.53

Technical Indicators

Market Signals
Indicator
DTSS
BIAF
Relative Strength Index (RSI) 43.59 40.46
Support Level $1.08 $1.60
Resistance Level $1.66 $1.74
Average True Range (ATR) 0.14 0.12
MACD 0.04 0.05
Stochastic Oscillator 33.05 37.79

Price Performance

Historical Comparison
DTSS
BIAF

About DTSS Datasea Inc.

Datasea Inc is a technology company that operates in two main segments. The first segment, Acoustic High-Tech, focuses on developing and applying acoustic technologies, such as ultrasound, infrasound, and mechanical wave effects, for applications like ultrasonic sterilization, neuro-regulation, acupoint stimulation, and environmental purification. The second segment, AI Multimodal Digitalization, integrates artificial intelligence with 5G networks and big data processing to create a proprietary multimodal data platform that combines text, voice, image, and video for real-time intelligent analysis and generation. The company generates all of its revenue from the People's Republic of China (PRC).

About BIAF bioAffinity Technologies Inc.

bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.

Share on Social Networks: